HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bárbara Domínguez-Asenjo Selected Research

Nifuratel

1/2021Ex Vivo Phenotypic Screening of Two Small Repurposing Drug Collections Identifies Nifuratel as a Potential New Treatment against Visceral and Cutaneous Leishmaniasis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Bárbara Domínguez-Asenjo Research Topics

Disease

2Leishmaniasis
01/2020 - 11/2019
1Cutaneous Leishmaniasis
01/2021
1Communicable Diseases (Infectious Diseases)
01/2020
1Tuberculosis (Tuberculoses)
01/2020
1Visceral Leishmaniasis (Kala Azar)
01/2019
1Parasitic Diseases (Parasitic Disease)
01/2019

Drug/Important Bio-Agent (IBA)

3Pharmaceutical PreparationsIBA
01/2021 - 01/2019
1NifuratelIBA
01/2021
1DNA (Deoxyribonucleic Acid)IBA
01/2020